news
FDA advisors to debate peptide compounding safety vs. gray markets
FDA advisors and peptide advocates are set to clash over whether compounding pharmacies should be allowed to offer unproven peptides. The move could either legitimize peptide access or crack down on a booming gray market where consumers often source these body-modifying compounds.
FDA advisors and peptide advocates are set to clash over whether compounding pharmacies should be allowed to offer unproven peptides. The move could either legitimize peptide access or crack down on a booming gray market where consumers often source these body-modifying compounds.
The architecture take
The FDA is finally looking head-on at the wild west of peptides, which for years have been readily available online and from compounding pharmacies without the same strict oversight as traditional drugs. This advisory panel is a serious signal that regulators are feeling pressure to either formalize safe access or completely shut down the avenues people are currently using for muscle growth, fat loss, and longevity. The real battle here isn't just about safety, though; it’s about control. If peptides move through regulated channels, expect prices to go up and access to become more medicalized. This debate will shape how you (or someone you know) can get your hands on things like BPC-157 or CJC-1295 in the future. Watch for a tightening of the supply chain and a push towards clinical oversight.